VEA
PCRX icon

Virtus ETF Advisers’s Pacira BioSciences PCRX Stock Holding History

Virtus ETF Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176K Buy
6,935
+170
+3% +$4.02K 0.07% 299
2026
Q1 		$153K Hold
6,765
– – 0.07% 286
2025
Q4 		$175K Hold
6,765
– – 0.08% 270
2025
Q3 		$174K Hold
6,765
– – 0.1% 231
2025
Q2 		$162K Hold
6,765
– – 0.1% 230
2025
Q1 		$168K Buy
+6,765
New +$162K 0.11% 234

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus ETF Advisers's PCRX Position: Q2 2026 in Review

Virtus ETF Advisers increased its Pacira BioSciences (PCRX) stake by 2.5% in Q2 2026, buying an estimated $4.02K and bringing the position to 6,935 shares worth $176K. The position accounts for 0.07% of the portfolio, ranked #299.

Virtus ETF Advisers first reported a position in PCRX in Q1 2025 and has held it in 6 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Virtus ETF Advisers held 6,935 shares of Pacira BioSciences worth $176K as of Q2 2026.
  • Virtus ETF Advisers bought 170 Pacira BioSciences shares in Q2 2026, an estimated $4.02K.
  • Pacira BioSciences made up 0.07% of Virtus ETF Advisers's portfolio in Q2 2026, its #299 holding.
  • Virtus ETF Advisers first reported a position in Pacira BioSciences in Q1 2025 and has held it in 6 quarters since.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.